Gene therapy for common congenital blindnesses shows promise

Reviewed by Emily Henderson, B.Sc.

Researchers at the Scheie Eye Institute in the Perelman School of Medicine at the University of Pennsylvania released initial data from a new clinical trial. The data suggest a new gene therapy for one of the most common forms of congenital blindness is safe and improved patients’ vision.

The therapy delivers working copies of GUCY2D to the eyes of patients who have severe vision impairments caused by mutations in the gene.

What is gene therapy?

Gene therapy is a technique that uses genes to treat or prevent disease by inserting a healthy copy of a gene into a patient’s cells, rather than relying solely on drugs or surgery. For patients with congenital blindness caused by inherited retinal conditions like Leber congenital amaurosis (LCA), gene therapy has moved well beyond the experimental stage and is now an FDA-approved congenital blindness treatment option.

Researchers are testing several approaches to gene therapy, including:

• Replacing a mutated disease-causing gene with a healthy copy.

• Inactivating, or “knocking out,” a mutated gene that is functioning improperly.

• Introducing a new gene into the body to help fight a disease.

Luxturna: the first FDA-approved gene therapy for congenital blindness

In 2017, the FDA approved Luxturna (voretigene neparvovec), a landmark gene therapy specifically designed for patients with vision loss caused by mutations in the RPE65 gene, one of the most well-known causes of LCA. Luxturna delivers a functional copy of the RPE65 gene directly into retinal cells using an adeno-associated virus (AAV) as a delivery vehicle. The AAV acts as a safe carrier, transporting the corrective gene into the cells that need it most without harming the patient’s DNA.

To be eligible for Luxturna, patients must have confirmed biallelic RPE65 mutations, sufficient viable retinal cells remaining, and be at least one year of age. Because the therapy targets living retinal tissue, earlier intervention tends to produce better outcomes, making timely genetic testing and diagnosis critical for families navigating a congenital blindness diagnosis.

Although gene therapy is a promising treatment for inherited blindness disorders, some cancers, and certain viral infections, not every patient qualifies, and ongoing research continues to expand who can benefit. Beyond RPE65-LCA, emerging clinical trials are investigating gene therapy for GUCY2D-related LCA, another inherited form of congenital blindness, with early dose-escalation results showing meaningful improvements in light sensitivity and functional vision in individual patients.

For patients and families in Southern California, understanding which genetic mutation drives vision loss is the essential first step in determining whether gene therapy is a viable path. A world-class retinal specialist can guide that evaluation and connect patients to both approved therapies and cutting-edge clinical trials.

What Is Congenital Blindness?

Congenital blindness refers to significant vision loss present at birth or developing within the first few months of life. It is not a single condition but rather an umbrella term covering a range of inherited and developmental disorders that affect how the eyes and visual system form and function. For families navigating a new diagnosis, understanding what is actually happening in the eye is the first step toward finding the right congenital blindness treatment.

The most common forms include:

• Leber Congenital Amaurosis (LCA): A group of inherited retinal dystrophies caused by mutations in genes like RPE65 and GUCY2D. LCA is a leading cause of severe vision impairment in children and is now at the center of some of the most exciting advances in gene therapy research.

• Retinopathy of Prematurity (ROP): A condition affecting premature infants in which abnormal blood vessels develop in the retina, sometimes leading to retinal detachment and permanent vision loss.

• Congenital Cataracts: Clouding of the eye’s natural lens present at birth that can block normal visual development if not treated promptly.

Causes range from genetic mutations passed down through families to infections during pregnancy, premature birth, and metabolic disorders. Early diagnosis is critical because the visual system is still developing in infancy, and timely intervention can meaningfully improve outcomes. If you are concerned about vision loss at any stage of life, speaking with a specialist as early as possible is always the right move.

Signs, Symptoms, and Diagnosis of Congenital Blindness

Recognizing congenital blindness early can make a real difference in how well a child responds to treatment. In many cases, parents notice something is off early, often within the first few weeks or months of life. Knowing what to look for is an important first step.

Some of the most common signs include:

• Eyes that do not track moving objects or faces by two to three months of age

• Nystagmus, which is an involuntary, rhythmic movement of the eyes

• Roving or wandering eye movements that appear unfocused

• Sensitivity to light, also called photophobia

• A noticeable clouding of the lens, which may indicate congenital cataracts

• Pressing or poking at the eyes, a behavior sometimes called the oculodigital reflex, which is commonly seen in children with Leber congenital amaurosis

• Delayed visual milestones compared to typical infant development

If any of these signs appear, a pediatric ophthalmologist should evaluate the child as soon as possible. Diagnosis typically involves a thorough eye exam, electroretinography to measure the retina’s electrical activity, and genetic testing to identify specific mutations. Genetic testing has become especially valuable because it can pinpoint the exact gene involved, which directly shapes which emerging treatments or clinical trials a child may qualify for. Early, precise diagnosis underpins any effective congenital blindness treatment plan.

Leber Congenital Amaurosis: The Most Common Form of Congenital Blindness

Once your child receives a diagnosis of congenital blindness, the next question is almost always: what type? Leber Congenital Amaurosis, commonly called LCA, is the most frequent cause of inherited congenital blindness in children, accounting for roughly 10 to 18 percent of all cases of congenital blindness worldwide. It affects an estimated 2 to 3 per 100,000 newborns, and while those numbers may sound small, the impact on a child and their family is enormous.

LCA is caused by mutations in at least 27 different genes responsible for normal retinal development and function. These genes control everything from how photoreceptor cells are built to how they process light signals. The most clinically significant subtypes involve mutations in the RPE65 and GUCY2D genes, both of which have become central targets in research on advanced treatments for congenital blindness.

Children with LCA typically experience severe visual impairment from birth or within the first few months of life. Common signs include nystagmus (involuntary eye movements), an absent or very sluggish pupil response to light, and oculodigital syndrome, in which children frequently press or rub their eyes. An electroretinogram, which measures the electrical activity of retinal cells, usually shows little to no response in patients with LCA.

The prognosis varies by affected gene. Some subtypes cause stable vision loss, while others are progressive. Understanding the specific genetic subtype is critical because, as research into emerging vision restoration therapies advances, researchers are developing targeted treatments for individual mutations rather than a one-size-fits-all approach to these inherited disorders.

Treatment Options for Congenital Blindness

Once a diagnosis is confirmed, the next question every family asks is: what can actually be done? The good news is that congenital blindness treatment has advanced dramatically over the past decade, and the options available today range from precision surgery to groundbreaking gene therapy.

The right treatment depends entirely on the underlying cause. Here is a look at the main approaches doctors use today:

Gene Therapy is one of the most exciting frontiers in congenital blindness treatment. The FDA-approved therapy Luxturna targets mutations in the RPE65 gene, a cause of Leber congenital amaurosis (LCA), and has restored meaningful vision in patients who previously had very little. Researchers are also actively investigating therapies targeting the GUCY2D gene, another common cause of LCA, with early clinical trials showing genuinely promising results. You can read more about emerging vision restoration technologies on our blog.

Surgical Intervention is the primary treatment for congenital cataracts and certain structural abnormalities. When cataracts are identified early, removing the clouded lens and fitting the child with corrective lenses or an intraocular lens implant can preserve the visual pathways during critical developmental windows.

Retinopathy of Prematurity (ROP) is treated with laser therapy or anti-VEGF injections to stop abnormal blood vessel growth before it causes permanent retinal damage.

Supportive therapies, including low vision aids, orientation and mobility training, and visual rehabilitation, play a vital role for patients with residual vision, helping them make the most of what they have while medical treatments continue to evolve.

What is the GUCY2D gene?

The GUCY2D gene is one of about 25 human genes whose mutations cause retinal problems that lead to severe vision impairment from birth or early childhood. This family of inherited retinal disorders, collectively known as Leber congenital amaurosis (LCA), accounts for a significant portion of childhood blindness worldwide.

The GUCY2D gene provides instructions for making a protein essential for normal vision. This protein is found in the retina—the specialized tissue at the back of the eye that detects light and color. Within the retina, the GUCY2D protein is located in light-detecting cells called photoreceptors. The retina contains two types of photoreceptor cells: rods and cones. Rods are needed for vision in low light, while cones are needed for vision in bright light, including color vision.

The GUCY2D protein is involved in phototransduction. When light enters the eye, it stimulates specialized pigments in photoreceptor cells. This stimulation produces an electrical signal that the optic nerve carries to the brain. The brain interprets this signal as vision. Once photoreceptors have been stimulated by light, they must return to their resting (or “dark”) state before they can be stimulated again. The GUCY2D protein is involved in a chemical reaction that helps return photoreceptors to their dark state after light exposure.

Normal copies of GUCY2D encode an enzyme in the key pathway that converts light into electrochemical signals. Without this enzyme, the pathway cannot recover, preventing the reset needed for further signaling. As a result, signals from rod and cone cells become very weak, causing severe vision loss.

Even in adults who have lived with this condition for decades, many light-sensing retinal cells may remain alive and intact despite their dysfunction. Thus, adding functional copies of GUCY2D via gene therapy could get those cells working again and restore some vision.

About the clinical trial of the GUCY2D gene

In 2019, Jacobson and co-investigator Artur V. Cideciyan, Ph.D., a research professor of Ophthalmology in the Perelman School of Medicine, began the first clinical trial of a GUCY2D gene therapy. The therapy is a single injection of a harmless viral vector that carries the gene. The solution is injected beneath the retina-initially in just one eye per patient.

Researchers have followed each patient for two years after treatment. In the new 2021 report, they described their findings after nine months in the first three patients treated.

Since those early findings, the GUCY2D trial has continued to build a compelling evidence base. By 2023, researchers had expanded the dose-escalation phase to include additional patients receiving higher viral vector concentrations, with several participants demonstrating meaningful gains in light sensitivity and functional vision under low-luminance conditions. These results reinforced what the initial cohort suggested: that restoring GUCY2D function in the photoreceptors can produce real, measurable improvements in patients who have lived with severely limited vision since birth.

In 2024, researchers at the University of Florida published results from a parallel LCA gene therapy program targeting a broader range of inherited retinal dystrophies. Their findings confirmed that subretinal delivery of adeno-associated viral vectors remains a safe and increasingly effective platform for treating congenital blindness, with no serious adverse events reported across multiple patient cohorts. The University of Florida data also highlighted that earlier intervention, ideally before significant photoreceptor loss, is associated with stronger and more durable visual recovery. This reinforces the clinical urgency of genetic testing and early diagnosis for children showing signs of LCA or related inherited retinal conditions.

Taken together, the progression from the 2019 trial launch through the 2024 multi-center findings represents one of the most promising arcs in modern retinal medicine, offering genuine hope for patients and families navigating a congenital blindness diagnosis.

What happened to the three study participants?

1. The first patient experienced a substantial increase in light sensitivity in the treated eye’s rod cells. Rod cells are more light-sensitive than cone cells and are chiefly responsible for low-light or “night vision.” This patient also showed improved pupil responses to light.

2. The second patient showed a smaller but sustained increase in rod cell light sensitivity. The improvement started about two months after the gene therapy.

3. The third patient showed no improvement in rod cell sensitivity. However, they did show significantly improved visual acuity over the nine-month follow-up period. The researchers tied this improvement to better function in the patient’s cone cells, the predominant cells for daylight and color vision.

“These initial results from the first-ever trial of a GUCY2D gene therapy are very encouraging and will inform our ongoing and future trials of this therapy,” said Cideciyan. No serious adverse effects were reported. Any side effects that occurred in the patients’ retinas resolved.

The gene therapy dose used in these first three patients was the lowest possible dose. The researchers plan to use higher doses going forward. So, they hope to see continued safety and greater efficacy in later-enrolled patients who receive higher doses.

The ongoing clinical trial is registered at clinicaltrials.gov as trial NCT03920007.

Written by The AGEI Educational Team

The Assil Gaur Eye Institute Education Team is dedicated to providing accurate, accessible, and patient-centered eye health information to support not only our patients, but the broader community as well. Working closely with our physicians and specialists, the team helps develop educational content designed to empower patients to better understand their vision, eye conditions, treatment options, and advances in ophthalmology. Our goal is to make complex medical topics easier to understand while upholding the highest standards of clinical accuracy, trust, and patient care.

The Assil Gaur Eye Institute Education Team is dedicated to providing accurate, accessible, and patient-centered eye health information to support not only our patients, but the broader community as well. Working closely with our physicians and specialists, the team helps develop educational content designed to empower patients to better understand their vision, eye conditions, treatment options, and advances in ophthalmology. Our goal is to make complex medical topics easier to understand while upholding the highest standards of clinical accuracy, trust, and patient care.

Medically Reviewed by Dr. Kerry Assil

Kerry K. Assil, MD, is regarded as one of the world’s foremost experts in refractive surgery, having made significant advances in the field with his numerous inventions. Additionally he has the unique distinction of having trained thousands of eye surgeons in the latest refractive surgical techniques. Dr. Assil has authored more than one hundred textbooks, textbook chapters and articles on refractive surgery and has appeared regularly on major television network news programs as a pioneer in refractive surgery. He also leads educational forums for other eye care professionals, which have included featured lectureships at Harvard University, Johns Hopkins University and Tokyo University.

Kerry K. Assil, MD, is regarded as one of the world’s foremost experts in refractive surgery, having made significant advances in the field with his numerous inventions. Additionally he has the unique distinction of having trained thousands of eye surgeons in the latest refractive surgical techniques. Dr. Assil has authored more than one hundred textbooks, textbook chapters and articles on refractive surgery and has appeared regularly on major television network news programs as a pioneer in refractive surgery. He also leads educational forums for other eye care professionals, which have included featured lectureships at Harvard University, Johns Hopkins University and Tokyo University.